CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth

CD47 is a glycoprotein of the immunoglobulin superfamily that is often overexpressed in different types of hematological and solid cancer tumors and plays important role in blocking phagocytosis, increased tumor survival, metastasis and angiogenesis. In the present report, we designed CAR (chimeric antigen receptor)-T cells that bind CD47 antigen. We used ScFv (single chain variable fragment) from mouse CD47 antibody to generate CD47-CAR-T cells for targeting different cancer cell lines. CD47-CAR-T cells effectively killed ovarian, pancreatic and other cancer cells and produced high level of cytokines that correlated with expression of CD47 antigen. In addition, CD47-CAR-T cells significantly blocked BxPC3 pancreatic xenograft tumor growth after intratumoral injection into NSG mice. Moreover, we humanized mouse CD47 ScFv and showed that it effectively bound CD47 antigen. The humanized CD47-CAR-T cells also specifically killed ovarian, pancreatic, and cervical cancer cell lines and produced IL-2 that correlated with expression of CD47. Thus, CD47-CAR-T cells can be used as a novel cellular therapeutic agent for treating different types of cancer.

[1]  Z. Eshhar,et al.  Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. , 2016, Annual review of pharmacology and toxicology.

[2]  K. Odunsi,et al.  The CD47 "don't eat me signal" is highly expressed in human ovarian cancer. , 2016, Gynecologic Oncology.

[3]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Katz,et al.  Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases , 2015, Clinical Cancer Research.

[5]  D. Roberts,et al.  Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. , 2013, Matrix biology : journal of the International Society for Matrix Biology.

[6]  H. Abken.  Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors. , 2015, Immunotherapy.

[7]  F. Bertucci,et al.  CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction , 2011, Proceedings of the National Academy of Sciences.

[8]  M. Hidalgo,et al.  Inhibition of Cd47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanism Statement of Translational Relevance , 2022 .

[9]  Daoud M. Meerzaman,et al.  A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer , 2016, Oncotarget.

[10]  I. Weissman,et al.  CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. , 2016, The Journal of clinical investigation.

[11]  D. Roberts,et al.  Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47* , 2010, The Journal of Biological Chemistry.

[12]  Theresa A. Storm,et al.  Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors , 2017, Science Translational Medicine.

[13]  M. Hidalgo,et al.  Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms , 2015, Clinical Cancer Research.

[14]  J. Chen,et al.  CD47: a potential immunotherapy target for eliminating cancer cells , 2016, Clinical and Translational Oncology.

[15]  Lu Zhang,et al.  Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[17]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[18]  V. Golubovskaya,et al.  FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo. , 2017, Frontiers in Bioscience.

[19]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  I. Weissman,et al.  Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells , 2012, Leukemia.

[21]  N. Hanna,et al.  Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery , 2016, Cancer Gene Therapy.

[22]  M. Sadelain,et al.  Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity , 2014, Science Translational Medicine.

[23]  F. Petrocca,et al.  Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy , 2017, Cancers.

[24]  V. Golubovskaya,et al.  Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy , 2016, Cancers.

[25]  D. Gilham,et al.  CAR T cells: driving the road from the laboratory to the clinic , 2014, Immunological reviews.

[26]  Ash A. Alizadeh,et al.  Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.

[27]  Qiang Sun,et al.  A fully human anti-CD47 blocking antibody with therapeutic potential for cancer , 2016, Oncotarget.

[28]  M. Maus.  Designing CAR T cells for glioblastoma , 2015, Oncoimmunology.

[29]  I. Weissman.  How One Thing Led to Another. , 2016, Annual review of immunology.

[30]  Jinquan Luo,et al.  Leveraging SBDD in protein therapeutic development: antibody engineering. , 2012, Methods in molecular biology.

[31]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[32]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[33]  J. Bading,et al.  Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma , 2015, Clinical Cancer Research.